Robert Azelby, EVP & Chief Commercial Officer at Juno Therapeutics, Inc. (JUNO), sold 58,262 shares at $68.10 ($4.0M) on 2018-01-17, disclosed to the SEC on 2018-01-19.
Open-market sale of $4.0M JUNO by EVP & Chief Commercial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $68.10 | 21,141 | $1.4M | 36.0% |
| 2 | $68.10 | 21,141 | $1.4M | 36.0% |
| 3 | $69.95 | 7,990 | $559K | 14.0% |
| 4 | $69.95 | 7,990 | $559K | 14.0% |
| Total | $68.61 avg | 58,262 | $4.0M | 100% |
| Filing → |
| JUNO | SELL | 2018-02-14 | $356K | — | Filing → |
| JUNO | SELL | 2018-02-09 | $600K | — | Filing → |
| JUNO | SELL | 2018-02-02 | $715K | — | Filing → |